Skip to main content

Table 2 Characteristics of the study population

From: Glucose associated NETosis in patients with ST-elevation myocardial infarction: an observational study

Age (years) 58 (51,67)
Female gender 39 (17.4)
BMI (kg/m2) 26 (24.4,28.7)
Waist circumference (cm) 100 (94,107)
Current smoking 109 (48.7)
Previous medical history
 Hypertension 58 (25.9)
 Hyperlipidemia 20 (8.9)
 Myocardial infarction 16 (7.1)
Acute phase
 Leukocyte count (× 109/l) 10.2 (8.5,12.4)
 Ischemic time (min)a 219 (139,382)
 HbA1c (%) 5.5 (5.3,5.8)
 Plasma glucose, start of OGTT (mmol/L) 5.3 (4.9,5.9)
 Plasma glucose, end of OGTT (mmol/L) 7.3 (5.9,8.8)
 AGR 105 (46.9)
 Peak Troponin T (μg/L) 4.7 (2.4,9.0)
Medication at hospital discharge
 Acetylsalicylic acid 224 (100)
 Clopidogrel 222 (99.1)
 Statins 221 (98.7)
 Betablockers 181 (80.8)
 ACE-inhibitors 36 (16.1)
 ATII antagonists 18 (8.0)
After 3 months
 Plasma glucose, start of OGTT (mmol/L) 5.2 (4.8,5.6)
 Plasma glucose, end of OGTT (mmol/L) 5.4 (4.5,7.1)
 AGR 50 (24.9)
 Infarct size, %b 14 (0,29)
 LVEF, %b 64 (56,70)
  1. Values are given as medians (25, 75 percentiles) or numbers (%) as appropriate. aDefined as time form symptom debut to PCI. bAssessed by Single photon emission computed tomography (SPECT). ACE angiotensin converting enzyme, AGR abnormal glucose regulation, ATII angiotensin II, LVEF left ventricular ejection fraction, OGTT oral glucose tolerance test